Sareum Holdings plc: Revision history

25 February 2024

• curprev 08:3608:36, 25 February 2024‎ 95.149.161.144 talk‎ 36,571 bytes +2‎ →‎What are the assumptions used to estimate the return? undo Tag: Visual edit
• curprev 08:1808:18, 25 February 2024‎ 95.149.161.144 talk‎ 36,569 bytes +497‎ →‎Cost of equity undo Tag: Visual edit: Switched
• curprev 08:0508:05, 25 February 2024‎ 95.149.161.144 talk‎ 36,072 bytes +5,808‎ →‎Risks undo Tag: Visual edit

24 February 2024

• curprev 23:5623:56, 24 February 2024‎ 95.149.161.144 talk‎ 30,264 bytes −25‎ →‎Competition undo Tag: Visual edit
• curprev 23:5323:53, 24 February 2024‎ 95.149.161.144 talk‎ 30,289 bytes −12‎ →‎Current strategy undo Tag: Visual edit
• curprev 23:4223:42, 24 February 2024‎ 95.149.161.144 talk‎ 30,301 bytes +40‎ →‎Financials undo Tag: Visual edit
• curprev 23:3123:31, 24 February 2024‎ 95.149.161.144 talk‎ 30,261 bytes +18,517‎ No edit summary undo Tag: Visual edit
• curprev 23:0923:09, 24 February 2024‎ 95.149.161.144 talk‎ 11,744 bytes −483‎ No edit summary undo Tag: Visual edit
• curprev 23:0023:00, 24 February 2024‎ 95.149.161.144 talk‎ 12,227 bytes +5,523‎ Undo revision 10488175 by 95.149.161.144 (talk) undo Tag: Undo
• curprev 22:5922:59, 24 February 2024‎ 95.149.161.144 talk‎ 6,704 bytes −5,523‎ Undo revision 10488174 by 95.149.161.144 (talk) undo Tag: Undo
• curprev 22:5822:58, 24 February 2024‎ 95.149.161.144 talk‎ 12,227 bytes +5,523‎ →‎Financials undo Tag: Visual edit: Switched
• curprev 22:3922:39, 24 February 2024‎ 95.149.161.144 talk‎ 6,704 bytes −80‎ No edit summary undo Tag: Visual edit: Switched
• curprev 22:3322:33, 24 February 2024‎ 95.149.161.144 talk‎ 6,784 bytes +6,115‎ No edit summary undo Tag: Visual edit: Switched

27 September 2022

• curprev 23:3823:38, 27 September 2022‎ Nick talk contribs‎ 669 bytes +669‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University..." Tag: Visual edit: Switched